PML-RARA Qualitative

Why get tested? To help diagnose acute promyelocytic leukemia (APL), a type of acute myeloid leukemia (AML); to help guide and/or monitor treatment of APL or to monitor for leukemia cells that remain after treatment (minimal residual disease) or for disease recurrence

Also known as: PML-RARA t(15;17)(q22;q12), Acute Promyelocytic Leukemia, AML-M3

Acute promyelocytic leukemia (APL) is a subtype of AML, accounting for about 10-15% of the total cases. The disease is identified by typical translocation t(15;17) (q22;q12), which contributes to the production of PML-RARA chimeric transcript being present in more than 90% APL patients. In normal condition, promyelocytic leukemia (PML) tales part in growth suppression, while the retinoic acid receptor ?(RARA) protein is involved in the promyelocyte differentiation process. After the fusion between PML and RARA, the original functions are a affected, leading to abnormal differentiation and growth of cells.

When you have results of a complete blood count (CBC) and/or signs and symptoms that suggest that you may have leukemia; periodically when you are being treated for APL and/or when you are in remission but need follow up.

Sample Requirement: Whole blood/ Bone Marrow

Test Preparation: No test preparation is needed.

Test Done by: 3500Dx Genetic Analyzer